Fabhalta Shakes Up the PNH Market in 15 Months as Soliris, Ultomiris, and Empaveli Compete and Voydeya and PiaSky Carve Their Niche
Spherix Global Insights recently released its latest findings from RealTime Dynamix™: Paroxysmal Nocturnal Hemoglobinuria Q1 2025 (US) an independent tracking study based on insights from 51 U.S.
pharmaphorum2d
EU gives narrower label to Apellis, Sobi's PNH drug
PNH is a rare, life-threatening disease of the blood characterised by destruction of red blood cells, blood clots and impaired bone marrow function, causing fatigue, recurrent infections and ...
pharmaphorum8d
Roche gets EU nod for subcutaneous PNH drug PiaSky
Roche's PiaSky has been approved by the European Commission, becoming the first therapy for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by monthly subcutaneous ...